A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study.

Szczegóły
Abstrakt

Tytuł:: A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study.
Autorzy:: Amadid H; Department of Epidemilogical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
Rønn PF; Department of Epidemilogical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
Bekker-Nielsen Dunbar M; Department of Epidemilogical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
Knudsen JS; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Carstensen B; Department of Epidemilogical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
Persson F; Department of Epidemilogical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
Jørgensen ME; Department of Epidemilogical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; National Institute of Public Health, University of Southern Denmark, Odense, Denmark.
Źródło:: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2021 Oct; Vol. 23 (10), pp. 2354-2363. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Oxford : Wiley-Blackwell, c1999-
MeSH Terms:: Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/epidemiology
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Pharmaceutical Preparations*
Cholesterol, LDL ; Cohort Studies ; Denmark/epidemiology ; Humans
References:: Eliasson B, Cederholm J, Eeg-Olofsson K, et al. Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register. Diabetes Care. 2011;34(9):2095-2100.
McEwen LN, Karter AJ, Waitzfelder BE, et al. Predictors of mortality over 8 years in type 2 diabetic patients: translating research into action for diabetes (TRIAD). Diabetes Care. 2012;35(6):1301-1309.
Jialal I, Bajaj M. Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol. 2009;20(1):85-86.
Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23 Suppl. 1):Iii2-Iii7.
Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-899.
Syvänne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350(Suppl. 1):Si20-Si23.
Kearney P, Blackwell L, Collins RA, et al. Cholesterol treatment trialists' (CTT) collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.
Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020;8(1):36-49.
Karlsson SA, Franzén S, Svensson A-M, Miftaraj M, Eliasson B, Andersson SK. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register. BMC Health Serv Res. 2018;18(1):900.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2019;41(1):111-188.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001;24(8):1335-1341.
Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98(23):2513-2519.
Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong ND. Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. BMJ Open Diabetes Res. 2015;3(1):e000132.
Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish civil registration system. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441-449.
Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(Suppl 7):30-33.
Carstensen B, Rønn PF, Jørgensen ME. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016. BMJ Open Diabetes Res Care. 2020;8(1):e001071.
Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(Suppl 7):38-41.
Andersen N, Hjortdal JØ, Schielke KC, et al. The Danish registry of diabetic retinopathy. Clin Epidemiol. 2016;8:613-619.
Andersen JS, de Fine ON, Krasnik A. The Danish national health service register. Scand J Public Health Suppl. 2011;39:34-37.
Carstensen B, Plummer M, Laara E & Hills M Epi: A package for statistical analysis in epidemiology. 2020. Version 2.41.
The National Laboratory Database. The Danish Health Data Agency. https://sundhedsdatastyrelsen.dk/da/registre-og-services/om-de-nationale-sundhedsregistre/doedsaarsager-og-biologisk-materiale/laboratoriedatabasen. Accessed July 15, 2019.
Ritschard G 2020 TraMineR v. 2.2-0.1.
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058.
Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic atorvastatin and health care costs. N Engl J Med. 2012;366(3):201-204.
Kopp TI, Delcoigne B, Arkema EV, et al. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Ann Rheum Dis. 2020;79(5):566-572.
Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464-474.
Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473-2481.
Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390-399.
Vrablik M, Catapano A, Wiklund O, et al. Understanding the patient perception of statin experience: a qualitative study. Adv Ther. 2019;36:2723-2743.
Kriegbaum M, Liisberg KB, Wallach-Kildemoes H. Pattern of statin use changes following media coverage of its side effects. Patient Prefer Adherence. 2017;11:1151-1157.
Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283.
Tokgözoglu L, Ozdemir R, Altindag R, et al. Role of media on discontinuation of statin therapy. Atherosclerosis. 2015;241(1):e205.
Wallach-Kildemoes H, Andersen M, Diderichsen F, Lange T. Adherence to preventive statin therapy according to socioeconomic position. Eur J Clin Pharmacol. 2013;69(8):1553-1563.
Ibfelt EH, Sorensen J, Jensen DV, et al. Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry. Clin Epidemiol. 2017;9:627-632.
Yang Z, Edwards D, Massou E, Saunders CL, Brayne C, Mant J. Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study. Clin Epidemiol. 2019;11:495-508.
Musich S, Wang SS, Schwebke K, Slindee L, Waters E, Yeh CS. Underutilization of statin therapy for secondary prevention of cardiovascular disease among older adults. Popul Health Manag. 2019;22(1):74-82.
Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J Am Coll Cardiol. 2017;69(18):2293-2300.
Rosinger A, Carroll MD, Lacher D, Ogden C. Trends in total cholesterol, triglycerides, and low-density lipoprotein in US adults, 1999-2014. JAMA Cardiol. 2017;2(3):339-341.
Taddei C, Zhou B, Bixby H, et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73-77.
Knudsen JS, Hulman A, Rønn PF, et al. Trends in HbA1c and LDL cholesterol in patients with type 2 diabetes receiving first-time treatment in northern Denmark, 2000-2017: population-based sequential cross-sectional analysis. Diabetes Care. 2020;43(2):e17-e19.
Vesper HW, Kuiper HC, Mirel LB, Johnson CL, Pirkle JL. Levels of plasma trans-fatty acids in non-Hispanic white adults in the United States in 2000 and 2009. JAMA. 2012;307(6):562-563.
Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624.
Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51(6):1546-1553.
Bartlett J, Predazzi IM, Williams SM, et al. Is isolated low high-density lipoprotein cholesterol a cardiovascular disease risk factor? New insights from the Framingham offspring study. Circ Cardiovasc Qual Outcomes. 2016;9(3):206-212.
Sone H, Nakagami T, Nishimura R, Tajima N, MEGA Study Group. Comparison of lipid parameters to predict cardiovascular events in Japanese mild-to-moderate hypercholesterolemic patients with and without type 2 diabetes: subanalysis of the MEGA study. Diabetes Res Clin Pract. 2016;113:14-22.
Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis. 2010;208(2):484-489.
Schandelmaier S, Briel M, Saccilotto R, et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017;6: CD009744.
Patterson CC, Karuranga S, Salpea P, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107842.
Contributed Indexing:: Keywords: atherosclerotic cardiovascular disease; dyslipidaemia; lipid-lowering drugs; pharmaco-epidemiology; type 2 diabetes
Substance Nomenclature:: 0 (Cholesterol, LDL)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
0 (Pharmaceutical Preparations)
Entry Date(s):: Date Created: 20210630 Date Completed: 20211018 Latest Revision: 20211018
Update Code:: 20240105
DOI:: 10.1111/dom.14478
PMID:: 34189831
: Czasopismo naukowe

Full Text Finder

Aim: To assess lipid-lowering drug (LLD) use patterns during 1996-2017 and examine lipid levels in relation to the use of LLDs and prevalent atherosclerotic cardiovascular disease (ASCVD).
Methods: Using a nationwide diabetes register, 404 389 individuals with type 2 diabetes living in Denmark during 1996-2017 were identified. Individuals were followed from 1 January 1996 or date of type 2 diabetes diagnosis until date of emigration, death or 1 January 2017. Redemptions of prescribed LLDs were ascertained from the nationwide Register of Medicinal Products Statistics. Data on lipid levels were sourced from the National Laboratory Database since 2010. LLD coverage was calculated at any given time based on the redeemed amount and dose. Trends in lipid levels were estimated using an additive mixed-effect model. Low-density lipoprotein cholesterol (LDL-C) goal attainment was assessed based on recommended targets by the 2011, 2016 and 2019 guidelines for management of dyslipidaemias.
Results: LLD use has decreased since 2012 and only 55% of those with type 2 diabetes were LLD users in 2017. A decline in levels of total cholesterol and LDL-C, and an increase in triglycerides, was observed during 2010-2017. Annual mean levels of LDL-C were lower among LLD users compared with non-users (in 2017: 1.84 vs. 2.57 mmol/L). A greater fraction of LLD users achieved the LDL-C goal of less than 1.8 mmol/L compared with non-users (in 2017: 51.7% and 19%, respectively). Among LLD users with prevalent ASCVD, 26.9% and 55% had, as recommended by current 2019 European guidelines, an LDL-C level of less than 1.4 mmol/L and less than 1.8 mmol/L, respectively, in 2017.
Conclusions: LLD use and LDL-C levels are far from optimal in the Danish type 2 diabetes population and improvement in LLD use could reduce ASCVD events.
(© 2021 John Wiley & Sons Ltd.)

Informacja